ADPT Stock Summary and Trading Ideas (Adaptive Biotechnologies | NASDAQ:ADPT)

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

What symbol and exchange does Adaptive Biotechnologies shares trade?

Adaptive Biotechnologies trades on the NASDAQ stock market under the symbol ADPT.

What is Adaptive Biotechnologies stock price doing today?

As of June 18, 2026, ADPT stock price climbed to $17.53 with 3,041,664 million shares trading.

What is Adaptive Biotechnologies's Beta?

ADPT has a beta of 1.11, meaning it tends to be more sensitive to market movements. ADPT has a correlation of 0.04 to the broad based SPY ETF.

How much is Adaptive Biotechnologies worth?

ADPT has a market cap of $2.81 billion. This is considered a Mid Cap stock.

How much money does Adaptive Biotechnologies make?

Last quarter Adaptive Biotechnologies reported $71 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.03.

What is the highest and lowest price Adaptive Biotechnologies traded in the last 3 year period?

In the last 3 years, ADPT traded as high as $20.76 and as low as $2.28.

What are the top ETFs holding Adaptive Biotechnologies?

The top ETF exchange traded funds that ADPT belongs to (by Net Assets): VTI, IWM, ARKG, VB, IWO.

Is Adaptive Biotechnologies (ADPT) a good investment?

ADPT has outperformed the market in the last year with a return of +67.4%, while the SPY ETF gained +26.9%. In the last 3 month period, ADPT beat the market returning +32.0%, while SPY returned +13.5%. However, in the most recent 2 weeks ADPT has underperformed the stock market by returning -3.0%, while SPY returned -1.1%.

What are the support and resistance levels for Adaptive Biotechnologies (ADPT)?

ADPT support price is $15.86 and resistance is $17.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADPT shares will trade within this expected range on the day.